Pharmalex Nordic ApS: Financial statements 2019
CVR: 37541540
Source: annual report 2019, Danish Business Authority
01/01/2019 – 31/12/2019
Pharmalex Nordic ApS (CVR 37541540) has filed annual accounts for 2019. In 2019, the company reported a gross profit of DKK 2,373,391 and a net result of DKK 2,397,696 compared with DKK 891,680 the year before. That is an increase of 25.5% compared with the year before. Equity in the 2019 report amounted to DKK 24,595,065. The solvency ratio was 41.1%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 2,373,391
- Profit/Loss
- DKK 2,397,696
- Equity
- DKK 24,595,065
- Total Assets
- DKK 59,852,057
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2019 | - | 2.4M | 2.4M | 24.6M | 2 |
| 2018 | - | 1.9M | 892K | 22.2M | 1 |
| 2017 | - | 100K | 495K | 2.9M | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2019
Pharmalex Nordic ApS has published its annual report for 2018. Gross profit came to DKK 1,890,960, and the net result was DKK 891,680.
About Pharmalex Nordic ApS
Pharmalex Nordic ApS is a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2016. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Åsa Pihlblad and Christopher Gauglitz. The company is owned by AmerisourceBergen International B.V.. The company has 1 employee (2026). In 2025, the company reported a gross profit of DKK 3,533,803 and a net result of DKK 1,709,691 compared with DKK -88,447,652 the year before. Equity in the 2025 report amounted to DKK -45,957,544.